Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03067480 · ClinicalTrials.gov registry record · NA
Comparison of 3 Versus 6-Month Use of CGMS in Non-Insulin Using T2DM Patients
A NA study, sponsored by East Tennessee State University.
- Terminated
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT03067480: Clinical Trial NA study, sponsored by East Tennessee State University.
NCT03067480 is a NA study that was terminated before completion, run by East Tennessee State University. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03067480, a NA study, was terminated before completion, sponsored by East Tennessee State University.
- TERMINATED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
To determine whether 3-month versus 6-month professional CGM utilization improves time spent in target range of 70-140mg/dl in patients with poorly controlled T2DM not treated with insulin.
Primary Outcome
Time sensor glucose is between 70-140mg/dl during a 72 hour collection period
Interventions
- DEVICE iPro2 Professional CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-06-06 |
| Est. Completion | 2019-09-30 |
| Phase | NA |
Why NCT03067480 stopped before completion
NCT03067480 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which iPro2 Professional CGM is the first listed.
NCT03067480 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03067480 about?
NCT03067480 is a clinical study titled "Comparison of 3 Versus 6-Month Use of CGMS in Non-Insulin Using T2DM Patients". To determine whether 3-month versus 6-month professional CGM utilization improves time spent in target range of 70-140mg/dl in patients with poorly controlled T2DM not treated with insulin.
What is the current status of trial NCT03067480?
This trial is currently terminated. It is a NA study. The enrollment target is 12 participants. The study started on 2017-06-06. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT03067480?
The interventions under investigation include: iPro2 Professional CGM (DEVICE).
Who is sponsoring clinical trial NCT03067480?
This trial is sponsored by East Tennessee State University, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03067480's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI